Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
Join this webinar to hear about the latest RMM technology and how it aligns with UPS testing criteria.

List view / Grid view

Dr. Elias Zerhouni

 

Dr. Elias A. Zerhouni (born April 12, 1951) is an Algerian-born American physician scientist radiologist and biomedical engineer. As a world-renowned national and international leader, Zerhouni is widely viewed as one of the leading authorities on emerging trends and issues in biomedical sciences and medical care. He spent much of his career on the faculty of the Johns Hopkins University school of Medicine.

From 1995 to 2002, he served as Executive Vice-Dean of Johns Hopkins School of Medicine and, in 2002, was appointed by President George W. Bush and confirmed by the Senate as the 15th Director of the National Institutes of Health, serving until 2008. In 2009, under the Obama Administration, he served as one of the country’s first presidential science envoys to foster scientific and technologic collaboration with other nations.

He also served as a senior fellow for the Bill and Melinda Gates foundation from 2009 through 2010. Since 2011, he is the President for Global Research and Development at Sanofi, one of the largest multinational pharmaceutical companies in the world.

Sanofi logo
Sanofi logo
news

Sanofi and Regeneron’s Dupilumab named “Clinical Advance of the Year” by Scrip Intelligence

Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc.…

25 November 2013 | By Sanofi

Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 2a study of dupilumab in asthma was named "Clinical Advance of the Year" by Scrip Intelligence at the 9th annual Scrip Awards. The award was announced last week by Scrip, a leading pharmaceutical…